€29.00 PSG.DE PharmaSGP (XETRA) pre-market 13 Mar 2026: Oversold bounce setup

We see a near-term oversold bounce forming for PSG.DE stock as PharmaSGP Holding SE trades at €29.00 in pre-market XETRA hours on 13 Mar 2026. Volume is elevated at 12,424 versus an average of 5,399, which supports a short-term mean-reversion trade. Fundamentals remain intact: EPS €1.68, P/E 17.26, and a market cap of €333,862,500.00. Investors watching an oversold bounce should weigh the company’s cash, margins and recent sector performance before acting. This write-up gives clear triggers, valuation context and a model-based forecast to frame a measured entry.

PSG.DE stock: pre-market facts and price action

PharmaSGP Holding SE (PSG.DE) is trading €29.00 on XETRA with a day low of €28.60 and day high of €29.00. The stock opened at €28.80, previous close was €29.00, year high is €30.00 and year low is €19.00.

Trading volume of 12,424 is 2.30x the average, a classic marker for an oversold bounce setup when price sits near short-term moving averages (50-day €28.52, 200-day €26.10).

Why an oversold bounce applies to PSG.DE stock

Short-term momentum shows a quick reversal potential because price is close to the 50-day average €28.52 and buyers are stepping in with higher-than-normal volume. The sector (Healthcare) has been modestly weak year-to-date, which can amplify intraday rebounds for well-capitalised smaller names.

For traders, the setup is clear: a prompt move above €29.50 on sustained volume would validate a tactical bounce while failure below €28.20 negates it.

Fundamentals and valuation for PharmaSGP Holding SE (PSG.DE)

PharmaSGP reports EPS €1.68 and a trailing P/E of 17.26, with revenue per share €8.14 and free cash flow per share €1.89. The company shows strong margins (gross margin ~90.49%) and a current ratio 2.68, indicating liquidity that supports a defensive bounce thesis.

Valuation flags: price-to-book is high at 9.12, and inventory days at 400.36 suggest working capital inefficiencies. A sensible long-term price target range is €26.00 — €34.00, with nearer-term trade targets noted below.

Technical setup, volume and trade triggers for PSG.DE stock

Momentum indicators show a quick mean reversion opportunity: price sits above the 50-day MA and within the Keltner channel (KC middle €29.00). Relative volume at 2.30 and a rising short-term average suggest buyers are already active.

Immediate trade triggers: a confirmed break and hold above €29.50 (target €31.50), stop under €28.00; conservative traders may scale in between €28.20 and €29.00.

Meyka AI grade, forecast and analyst view on PSG.DE

Meyka AI rates PSG.DE with a score out of 100: Score: 79.07 | Grade: B+ | Suggestion: BUY. This grade factors S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts and analyst consensus.

Meyka AI’s forecast model projects €27.36 for one year, €29.48 in 3 years and €31.56 in 5 years; the one-year projection implies -5.64% vs the current €29.00, while the five-year outlook implies +8.84%. Forecasts are model-based projections and not guarantees. See also PharmaSGP company news and peer context on Investing.com and our platform page at PharmaSGP on Meyka.

Risks, catalysts and how to size a trade on PSG.DE stock

Key risks include inventory build-up, a high price-to-book ratio and sensitivity to consumer OTC demand across Europe; these can cap rallies. Catalysts that support a sustained bounce are any positive regional sales updates, margin improvements, or an upgrade from major research houses.

Position sizing guidance: limit single-trade exposure to no more than 1.5% of a diversified portfolio for a speculative oversold bounce, and use a stop-loss near €28.00 to control downside.

Final Thoughts

Short-term traders can treat PSG.DE stock as a disciplined oversold bounce candidate while longer-term investors should weigh valuation and inventory metrics. The pre-market action shows €29.00 price, elevated 12,424 volume and proximity to the 50-day average €28.52, which supports a tactical bounce attempt. Meyka AI’s model projects a one-year figure of €27.36 (implying -5.64% vs €29.00) and a five-year projection of €31.56 (+8.84% upside). We recommend a two-tier approach: traders look for a confirmed break above €29.50 with a short-term target of €31.50 and a tight stop under €28.00; investors should monitor margins, inventory turn and any sales updates before increasing exposure. These takes come from Meyka AI-powered market analysis platform and are model-driven; they are not investment advice and are not guaranteed.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.